From 'omics' to complex disease: a systems biology approach to gene-environment interactions in cancer by Knox, Sarah S
HYPOTHESIS Open Access
From ‘omics’ to complex disease: a systems
biology approach to gene-environment
interactions in cancer
Sarah S Knox
Abstract
Background: Cancer is a complex disease that involves a sequence of gene-environment interactions in a
progressive process that cannot occur without dysfunction in multiple systems, including DNA repair, apoptotic
and immune functions. Epigenetic mechanisms, responding to numerous internal and external cues in a dynamic
ongoing exchange, play a key role in mediating environmental influences on gene expression and tumor
development.
Hypothesis: The hypothesis put forth in this paper addresses the limited success of treatment outcomes in clinical
oncology. It states that improvement in treatment efficacy requires a new paradigm that focuses on reversing
systemic dysfunction and tailoring treatments to specific stages in the process. It requires moving from a
reductionist framework of seeking to destroy aberrant cells and pathways to a transdisciplinary systems biology
approach aimed at reversing multiple levels of dysfunction.
Conclusion: Because there are many biological pathways and multiple epigenetic influences working
simultaneously in the expression of cancer phenotypes, studying individual components in isolation does not allow
an adequate understanding of phenotypic expression. A systems biology approach using new modeling
techniques and nonlinear mathematics is needed to investigate gene-environment interactions and improve
treatment efficacy. A broader array of study designs will also be required, including prospective molecular
epidemiology, immune competent animal models and in vitro/in vivo translational research that more accurately
reflects the complex process of tumor initiation and progression.
Introduction
Large population-based studies have provided important
information concerning trends in morbidity and mortal-
ity, and have helped identify genotypes, behaviors, and
environmental factors associated with multiple chronic
diseases. Based on this knowledge, it has become
increasingly evident that the chronic diseases responsible
for the greatest mortality, e.g., cardiovascular disease
and cancer, occur in a context of interaction between
multiple genes, environmental risk factors and epige-
netic changes. Although the complexity of causal factors
associated with these diseases has been known for
some time, our understanding of gene-environment
interactions has not kept pace. For a long time it was
believed that the relationship between genes and envir-
onmental factors was essentially additive, i.e., that geno-
types explained a certain fixed amount of the population
variance in disease prevalence and that when environ-
mental factors were added to genotype, heredity and
environment summed to 100 percent.
VV V phenotype genotype enviornment =+
Interactions were defined statistically. In the simplified
example below (equation adopted from Pedersen NL,
[1]) the phenotype of Twin A is predicted from the phe-
notype of Twin B plus the environment, plus the inter-
action of these 2 main effects.
Twin A Twin B Environ Twin B E phenotype phenotype phenotype =+ + × (n nviron)
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tions do not accurately reflect the complexity of non-
linear interactions at a molecular level. Gene expression
and function can vary based on the surrounding micro
environment, which varies in response to multiple inter-
nal and external cues. The mechanisms responsible for
these variations in response to the surrounding environ-
ment are the epigenome in conjunction with cis-regulat-
ing mechanisms. DNA is analogous to computer
hardware and the software needed to program it is the
epigenome [2]. Cells throughout the body are for the
most part, genetically identical. What differentiates one
tissue or organ from another is gene expression. Just as
gene expression varies between organs, it can also
respond and adapt to multiple environmental cues -
dietary nutrients, smoking, other toxicant exposure, and
psychosocial stress.
Most environmental factors that precipitate epigenetic
changes affect multiple systems simultaneously. Thus,
the overall effect depends on how these functional
changes interact. Two different exposures (e.g., diet and
smoking) may have influences on the gene expression of
a single polymorphism that are mutually antagonistic or
synergistic. The ultimate expression of that allele will
depend on the combined effect including enzymes, tran-
scription factors, genes, and signaling pathways. Thus,
the ‘genetics’ component of the phenotype is neither sta-
tic nor additive. Gene expression is dynamic. In addition
to the complex biology of genotype - environment inter-
actions, epistatic (gene × gene) interactions, are also
environmentally influenced via the epigenome. This
means that a single gene can have different functional
responses, depending on its ambient surroundings. A
good illustration is the P53 tumor suppressor gene. P53,
which involves complex signaling pathways central to
tumor development, responds to a broad range of sig-
nals that determine whether the cellular response will
be DNA repair, cell metabolism, autophagy, apoptosis or
cell cycle arrest [3,4].
This explains why genes and environment cannot be
understood with linear statistical equations. The effects
of the environment on phenotype are much too com-
plex to be adequately accounted for in an additive
model. It also clarifies how the environment can interact
with genotype without there being a statistical ‘main’
effect for either genotype or environment. The inter-
twining of genetics, epigenetics and environmental fac-
tors is one of nonlinear dynamically interacting systems.
These interactions have major implications for study
design and data analysis. The term complexity applies
not just to the number of causal exposures (e.g., smok-
ing, diet, toxicity, genotype) but to the multiplicity of
integrated systems that interact in response to these
exposures. Using a statistical model that first examines
the significant (main) effectso fi n d i v i d u a lf a c t o r sa n d
next interactions between two main effects, would be
inappropriate where several factors not having ‘main’
effects are working synergistically, but not additively, to
achieve a result that none of them could achieve alone.
Nonlinear dynamical interactions are also highly rele-
vant for the design of genome wide association studies
(GWAS), which examine associations between a geno-
type and phenotype in populations after controlling for
relevant confounders. The design of these studies does
not take into consideration interactions that allow the
same genotype to alter function in different contexts,
leading to multiple phenotypes being associated with the
same genotype. The naïve assumption of GWAS design
is that, regardless of context, a genotype will be asso-
ciated with the same phenotype. The failure to replicate
in many candidate gene studies [5,6] is poorly under-
stood but has variously been attributed to factors such
as epistasis, population drift, population stratification,
and genetic diversity. These are all important factors.
However, the multiple nonlinear influences on gene
expression are the primary culprit limiting the useful-
ness of GWAS design for investigating causal influences
of genotype on phenotype. Rather than assuming that
the candidate gene is not relevant because the results
are not significant, we should be asking whether there
are particular circumstances under which the allele in
question explains a significant amount of the variance
and others where it does not.
New methodologies and mathematics are being devel-
oped to generate predictions about interactions at multi-
ple levels of complexity, and to test these predictions
against experimental data so that the accuracy of predic-
tions is continually refined. The focus of this article will
be on the role of systemic malfunction in the etiology of
cancer, and the necessity of finding new approaches to
clinical oncology.
Biological Complexity
Complexity in Dynamical Systems
The ‘whole’, i.e., the phenotype or disease condition that
we are trying to treat and prevent, is greater than the sum
of its parts. This is why complex diseases cannot be under-
stood by studying individual genes, signaling pathways,
behaviors or environmental exposures without observing
them in a functional context. The emergence of new prop-
erties evolves as the level of complexity increases: from
molecules to proteins, from proteins to tissues and so on.
Hemoglobin is a good example. The part of the blood that
transports oxygen, is composed of four hemoproteins [7]
which do not have the ability to transport oxygen. How-
ever, when they combine, some of their original properties
and functions, such as hydration patterns, are lost. What
emerges is a property that the individual molecules did
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cept is important because it is a good analogy for complex
diseases, which involve many gene-gene and gene-environ-
ment interactions that create emergent properties not pre-
sent in the individual components.
Cells and organisms are also dissipative because they
are open systems that continually exchange energy and
matter with their surrounding environments [8]. This
exchange, occurring under ever varying conditions, cre-
ates a dynamic in the body’s biochemistry. An example
of how the state of flux plays out at the molecular level
can be illustrated by conformer molecules. These mole-
cules can assume different 3-dimensional spatial
arrangements without breaking their chemical bonds by
having parts of the molecule simply rotate around a sin-
gle bond. The shape of a conformer can be influenced
by its surroundings. When in water, it will hide its
hydrophobic side-chains in a core and expose its polar
groups to the solvent. Their ability to fluctuate in this
manner is dependent not only on the environment but
on their chemical composition (e.g., their chemical
bonds). The number of possible geometric forms that a
molecule can assume is called the conformational space
[7], which constitutes the expression of different charac-
teristic states or properties of the molecule. “The fluc-
tuation of form and function generates a number of
molecular states, which are snapshots of the molecule at
a given point in time” [7]. The range of possible proper-
ties is called the property space. At each level of com-
plexity the property space changes.
This flexibility serves an adaptability of function
necessary for the dynamic equilibrium that contributes
to the survival of the organism. The term ‘dynamic equi-
librium’ is used instead of ‘homeostasis’ to illustrate that
the state space is limited but not static in healthy indivi-
duals (e.g., heart rate stays within in a limited range but
varies greatly over time). This also applies to the DNA
strand (the double helix of base pairs), which is wound
around 8 histone proteins and packed into nucleosomes
that have the ability to control access to the DNA by
polymerases and transcription factors. This efficient
packaging fits the DNA into the nucleus and controls
when and in what context the gene will be expressed.
However, there is an ongoing exchange between the
nucleus, the cell and the extra cellular environment that
influences the shape of the nucleosome, promoters,
transcription factors and other molecules. Thus, the
nucleosomes are dynamic and can undergo conforma-
tional fluctuations in the temporal range of seconds to
microseconds [9]. A molecule’s state at any given time
is not just determined by the individual properties of its
subcomponents but by the system as a whole. (For a
more complete discussion of the dynamics of living
states, please see Agutter & Wheatley [10].
This means that when we do an in vitro experiment
and expose a gene, receptor or signaling pathway to a
specific substance, what we are observing is how that
molecule behaves when exposed to that specific sub-
stance in that particular context (e.g., in vitro,o rin vivo
in Drosophila or an immune-compromised mouse). If
we are using an animal model, it is highly likely that the
reaction will vary depending on how well the immune
system functions and on the mode of exposure (e.g.,
intraperitoneal injection, inhalation). The transition
from how a rodent responds to how a human responds
is another large leap. We must remember that even
when a rodent gene is very similar to that of humans,
the mouse itself is very different [11]. This does not
reduce the importance of in vitro or animal model
experiments, but requires caution in how we interpret
them. An individual gene, receptor or signaling pathway
may be a marker of disease progression or increase our
ability to predict outcome at a certain stage of disease,
and yet not lead to an understanding of how this factor
interacts systemically with respect to host susceptibility
or etiology. If we don’t understand etiology, then our
treatment methods may be focusing on the wrong tar-
gets. The wheels are significantly associated with the
movement of a car uphill but do not explain the car’s
ability to accelerate. Without a motor, the wheels,
would in fact, only revolve in a downhill direction. So,
although wheels are an integral aspect of a car’ss t r u c -
ture and function, examining a wheel in isolation does
not provide sufficient information to help us understand
what enables a car to accelerate. To understand that, we
need more information about how the wheels, motor,
transmission and fuel systems work together. In other
words, we need knowledge about the integrated function
of the whole system.
To summarize, confining research to a particular level,
be it the molecular, tissue, animal, or population, is not
sufficient for unraveling complex diseases in humans. It
is becoming increasingly evident that only transdisciplin-
ary research with a broader range of study designs and
new methods that facilitate the understanding of non-
linear systems will be able to accomplish this. Mathema-
tical tools continue to be developed to grapple with the
problem of modeling and understanding the complexity
of these dynamic interactions.
Nonlinear Dynamics
The term nonlinear dynamics refers to changing condi-
tions that do not occur in a proportional or linear man-
ner. An example of a linear relationship would be a
situation where every increase in the number of cigar-
ette packs smoked is associated with a proportional
decrease in months of survival time in the smoker. A
nonlinear relationship can be exemplified by a drug that
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becomes toxic and can result in death above this thresh-
old. The dynamics of chemical and biological systems
are nonlinear, which has important implications for
function because they exhibit varying spatiotemporal
patterns depending on the health of the system as a
whole. Most of the systems in the body, including brain
waves, neuroendocrine secretions, heart rhythms, chemi-
cal processes, and epigenetic mechanisms are nonlinear
and also dynamic. This allows them to fluctuate in
response to the body’s needs and varying environmental
demands, to assure survival.
Nonlinear mathematical methods have been successful
in explaining the dynamics of chemical and biological
systems as well as outcomes in clinical medicine [12].
Even at the molecular level, it has been demonstrated
that introns (noncoding DNA sequences) have remark-
ably long range correlations that can extend over thou-
sands of base pairs, while coding sequences do not
[13,14]. Clinically, nonlinear methods have improved
prognostic ability in the fields of cardiology (e.g., pre-
dicting cardiomyopathy [12]), sudden death [15] and
aging [15]. By enhancing statistical probability analyses
with mathematical methods from physics, knowledge
and interpretation of variation in multiple biological sig-
nals have been greatly enhanced. Through these
advances, we have learned that the concept of homeos-
t a s i sw h i c hw a sp r e v i o u s l yu s e dt od e s c r i b et h ed e s i r e d
state of bodily systems is a misnomer. Stasis is not a
healthy condition at all. Health is maintained by a state
of dynamic equilibrium which allows the body to adapt
and respond while maintaining stability.
One of the areas of medicine that has been difficult to
resolve with linear methods is the unpredictability of
systems that suddenly shift from being clinically stable
to being clinically unstable (e.g., asthma attacks, epilep-
tic seizures). It is often the case that there is little visible
indication that the transition is about to take place [16].
A recent review of these nonlinear transitions [16]
described a condition of ‘critical slowing down’ that
seems to be generic across systems. Before the critical
transition points (known as ‘catastrophic bifurcations’)
the system’s ability to respond to small perturbations
decreases, moving the system away from flexibility
towards stasis. The critical slowing down begins long
before the bifurcation point, so the ability to respond to
small perturbations can be used as an indicator of how
close the system is to a critical point. However, in clini-
cal situations such as chronic asthma, it is usually
impossible to continually test reactions to pre-deter-
mined stimuli. Therefore, a technique for monitoring
the state of a biological system with mathematical signal
analysis has been developed. The slowing down process
in a system’s responses indicates that the moment-to-
moment signal fluctuations are becoming increasingly
similar. Thus, autocorrelations in temporal patterns can
b ear e l i a b l ei n d i c a t o ro fh o wc l o s et h es y s t e mi st oa
critical shift. Similar techniques can also be adopted for
spatial patterns.
Systems Biology
Increasing awareness of the complex dynamics of living
systems has led to a new field of research called systems
biology. It evolved partly because of the need for compu-
tational methods that can deal with the nonlinearity in
signaling pathways in relationships between genotype
and phenotype. This need developed from the realization
that genetic diversity does not account for the diversity
of physiological functions, nor does cis-rgulatory control
of DNA lead directly to an understanding of organism
function [17]. The poor reproducibility of candidate gene
studies in predicting phenotype and the failure to explain
variability in phenotype by reducing systemic complexity
to the properties of the subcomponents has led to the
recognition that new approaches are required. Although
systems biology tends to focus on molecular networks, it
differs from traditional molecular biology in that it uti-
lizes analytic techniques designed to account for emer-
gent properties arising from the context, adaptability and
plasticity of function [18] in signaling pathways that con-
tribute to disease phenotypes and treatment responsive-
ness. It has been demonstrated that the use of nonlinear
dynamical measures works equally as well for ‘omics’
data as for biological rhythms represented by the ECG
and EEG [19]. Although systems biology has been
defined in various ways, it usually includes the quantita-
tive analysis of dynamic interactions among several com-
ponents of a system (biological, chemical), with the
intent of understanding the behavior of the system as a
whole rather than the behavior of the individual compo-
nents [20,21].
Rather than compartmentalizing individual risk factors
(e.g., blood pressure or lipid concentrations in CVD)
a n dt r e a t i n gt h e ma si ft h e yw e r es e p a r a t ea n di n d e p e n -
dent, systems biology examines their interactions and
the complexity of systemic response to treatments. The
key concept is that a treatment intended for one parti-
cular symptom (e.g. tumor growth) affects multiple
other systems; hence an understanding of these interac-
tions is essential for treatment efficacy. If a treatment
reduces tumor size but simultaneously reduces immuno-
logic responsiveness, then it may inadvertently promote
new tumor growth. This is why a systems biology
approach is particularly useful with complex diseases
that involve multiple organ systems and etiologic contri-
butors. It would not be necessary or appropriate in a
straightforward case of a bacterial infection in a young
and otherwise healthy person where a simple antibiotic
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with several co-morbidities who is being treated with
multiple pharmacologic regimens presents a more com-
plex clinical picture and would benefit from a more sys-
tems oriented approach.
Chronic conditions that develop over a long time
course and have multiple genetic and environmental
contributors cannot be properly understood without
studying the dynamic spatial and temporal interactions
of the affected systems. Although this paper focuses on
cancer, the concepts apply to many other conditions
(e.g., cardiovascular disease), as well. These chronic con-
ditions could greatly benefit from a multidisciplinary
systems biology approach. The utility of systems
dynamics for understanding host susceptibility and the
consequent implications for the design of research
related to treatment is relevant to both.
Cancer
The Cancer Pharmacology Paradigm
Cancer pharmacology has been a difficult area of
research. Despite tremendous effort and billions of dol-
lars invested, only marginal improvements in treatment
outcome have been achieved since the ‘war on cancer’
was first declared. A recent review concludes that oncol-
ogy has one of the poorest records for investigational
drugs in clinical development [22]. It is time we exam-
ined the reasons and planned a strategy for addressing
them.
P a r to ft h ep r o b l e mm a ya c t u a l l yb et h ef r a m eo f
reference for pharmacologic models of cancer [23]. The
current conceptualization of cancer as a morphological
entity that must be attacked and eliminated has achieved
only limited success [23]. This paradigm focuses on
attacking cancer the way we attack and kill invading
bacteria. The problem with this approach is that cancer
cells are not alien invaders; they are part of our own
bodies.
Drugs used in the treatment of cancer can essentially
be divided into those that target essential functions and
those that target non-essential functions [22]. An exam-
ple of a drug that targets ‘non-essential’ functions is the
estrogen-receptor modulator, tamoxifen (an antihormo-
nal), which targets specialized tissue (breast epithelium)
that is non-essential for life. Traditional cytotoxic phar-
maceuticals target essential functions like cell division,
which explains why their toxicity is not specific but
affects multiple systems in the body. There are other
drugs developed more recently that inhibit parts of key
signaling pathways such as kinases [22] and are intended
to be more specific and less destructive. An example is
the drug, Imatinib which is used for chronic myeloid
leukemia. Those that target upstream functions in sig-
naling networks have less general toxicity than those
that aim farther downstream. However, many of these
drugs also affect other crucial survival and proliferation
pathways whose destruction is more deleterious [22].
The paradigm for all of these drugs is the assumption
that cancer can be treated by targeting and either inhi-
biting or destroying a single function. As we have seen
from the discussion of systems biology, this logic does
not fit with what we know about gene-environment
interactions and the paradigm has not met with a great
deal of success.
Schipper et al. [23] think that we need to shift our
perspective towards seeing malignant neoplasms as the
result of a process of dysregulation. The importance of
this concept, is that dysregulation is often reversible [23].
This shifts the paradigm from one that targets the kill-
ing of renegade cancer cells [24], to one that focuses on
reversing the complex interactions involved in systemic
dysregulation [25], Cell behavior (e.g., out of control
proliferation) is seen as a result of regulatory imbalance
and not as the initiating factor. From a pharmacological
perspective, this would require a completely new
approach.
Schipper et al., illustrate their point with the example
of a scientist using a genetically engineered mouse to
investigate the effect of protein A on protein B. The
mouse is engineered to knock out either A or B so that
its function can be investigated by examining how the
system functions without it. The advantage of this
model is that it facilitates understanding of the general
function of the gene or protein when the dysfunction is
structural. However, it does not mimic the process by
which a gene or protein becomes dysfunctional in an
intact organism. Humans are not born lacking entire
genes (except in very rare cases). In humans, cancer
develops in intact systems, which become dysfunctional
through interactions with environmental, immunologic,
genetic, viral, epigenetic, behavioral, and other factors.
The immune-incompetent animal model supports the
theory that immune-incompetence promotes cancer, but
it does not mimic the process that leads to tumor initia-
tion and progression in humans. A functional change of
A or B (e.g., under expression of a tumor suppressor
gene) in an intact organism triggers a response from
other systems. Sometimes the response is successful and
the dysregulation is corrected (e.g. through tumor sup-
pression, apoptosis, etc.), in others it is not successful
and dysfunction continues or worsens. Both rats and
humans have natural defense mechanisms against neo-
plasia, which is why it is so difficult to get a tumor to
develop in an immunocompetent animal [26]. The pro-
tective systems respond (e.g., to injected cancer cells) by
repairing the damage, eliminating the aberrant cells, or
suppressing the process of tumor formation. The sug-
gestion made by Schipper et al. that changing the
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morphological entities to cancer as a process of regula-
tory imbalance would address some of the failures by
changing research strategies. The fact that cancerous
cells can be inserted into an animal and not develop
into a tumor, reinforces the theory that it is not the char-
acteristics of the cells themselves, that result in cancer,
but the properties emerging from the interaction between
the cell and other response systems.
The receptors, genes, cells and signaling pathways that
have been targets for pharmacologic intervention are all
part of dynamic networks. These networks are charac-
terized by emergent properties and an adaptability of
function that allows them to respond to the needs and
demands of the surrounding environment [27,28].
Above all, they are characterized by the fact that they
are not isolated but continually interact with each other.
This is why drugs that target single functions can have
such deleterious ‘side’ effects. For this reason, the
knockout model commonly used in cancer drug devel-
opment (the nude mouse model) may be a poor model
for prediction of response systems that are relevant to
cancer etiology and progression [8]. These mice do not
mimic what happens in the natural development of can-
cer because there is no adaptability or flexibility in the
part of the system that is genetically engineered. Dele-
tion of function is permanent. This does not mean that
we should stop using this model but that in order to get
from ‘omics’ to complex disease phenotypes, we need to
complement it with other methods, such as molecular
epidemiology, that facilitate the examination of the pro-
cess of cancerogenesis in humans. The immunodefi-
ciency that allows cancer to grow can take many forms
and evolves over many years. Sudden total structural
deletion (i.e., knockout) doesn’t occur. The body is
equipped with multiple DNA repair, immune and tumor
suppressor mechanisms that usually destroy aberrant or
mutated cells. These systems can become dysfunctional
through aging, infection, or multiple environmental
onslaughts. When that occurs, host susceptibility to car-
cinogens increases. Once a tumor is initiated, it changes
the interactions between systems, modifying the envir-
onment and being modified by it. This perspective on
cancer etiology defines cancer as an evolving process of
regulatory imbalance. The problem of treatment and
prevention then becomes one of how to identify impor-
tant stages in this process and target an appropriate
intervention to reverse the dysregulation as early as
possible.
Epigenetic Mechanisms
The field of epigenetics is providing data that may help
us find some answers to these questions. Although
tumors are localized at individual sites (e.g., lung, colon,
breast), malignancy is characterized by global gene
expression changes including genome wide hypomethy-
lation of DNA and chromosomal modification [29],
including hypoacetylation of chromatin [30-33]. Along
w i t ht h e s eg l o b a lc h a n g e s ,t h e r ea r es i t es p e c i f i ce p i g e -
netic modifications such as hypermethylation (suppres-
sion) of CpG islands in promoter regions that in a
healthy system would lead to tumor suppression [29].
These types of epigenetic changes have a stronger associa-
tion with tumor progression than do specific mutations
[34], providing additional support for the theory that
cancer indeed involves a systemic process. According to
a review of genetics and epigenetics in cancer [34], the
types of expression changes that are ubiquitous in can-
cer, namely methylation, loss of imprinting and chroma-
tin modifications, can influence phenotypes through
regulation without underlying changes (e.g. mutations)
in the sequence of DNA base pairs. There are multiple
mechanisms through which expression changes occur
including (but not limited to) the addition of molecules
to DNA (methylation), neutralizing of the charge
between DNA and histone tails (around which the DNA
is wrapped) allowing easy access by transcription factors,
post translational modifications and loss of imprinting.
The changes that these modifications reflect are not
confined to single functions or signaling pathways but
a r eg e n o m ew i d e .G e n en e t w o r k sa r en o r m a l l yq u i t e
robust because their nonlinear (scale-free) structure
means that the majority of nodes have only one or two
links, while a few have many more. This helps to main-
tain equilibrium by reducing the probability that mal-
function in a single gene (node) in the network will
knock out the whole system. Therefore, the genome
wide expression changes occurring in cancer indicate
multiple systemic malfunctions. This pinpoints the diffi-
culty in explaining tumor initiation and progression
with single mutations, despite the fact that mutations
sometimes serve as markers of tumor progression. The
multiple genome wide expression changes that are com-
mon to most cancers may contribute to the difficulty in
replicating some of the candidate gene studies related to
cancer.
The fact that the same candidate gene can be asso-
ciated with different phenotypes depending on global
gene expression patterns lies at the heart of gene-envir-
onment interactions. It isn’t the gene itself, but its
expression (behavior) in the context of other systemic
factors that determines risk. Thus, the same genotype
may be associated both with normal and abnormal
behavior. Metastable epialleles are loci that can be epi-
genetically modified in a manner that is variable and
reversible so that a distribution of phenotypes can
be produced from genetically identical cells [11]. This
is another reason why the effects of genes and
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els. Biologically, genes are up- and down-regulated in a
dynamic, ongoing manner based on changing demands
and inputs to the system. Since the epidemiologic data
on cancer clearly indicate the etiological importance of
environmental factors, gene expression and epigenetic
mechanisms are receiving increased focus and impor-
tance as mediating mechanisms in the characterization
of tumor initiation and progression.
The concept of cancer as a process rather than a
structural entity is also illustrated by research on can-
cers associated with well known risk factors (e.g., lung
cancer). Smoking is a documented risk factor [35] that
it is responsible for about 130,000 deaths annually from
active and 22,200 from passive smoking [36]. However,
although 80% - 90% of lung cancer patients are current
or former tobacco smokers, only 10% - 15% of smokers
actually develop lung cancer [37,38], and about 15% of
men and 53% of all women with lung cancer worldwide
(percentage of women is lower in the U.S. [39]) were
never smokers [40]. These epidemiological findings
strongly suggest that there are host differences in sus-
ceptibility to lung cancer and that the likelihood of a
smoker developing lung cancer depends not only on
how much and how long s/he has smoked but also on
the presence of other etiological risk factors. Such fac-
tors include ‘at risk’ genotypes [41,42], arsenic exposure
[43,44], low socioeconomic status [45], and other envir-
onmental carcinogens. Population-based studies are an
important complement to in vitro and animal studies
because they identify real-life behavioral and environ-
mental risk factors. However, to be useful, these studies
should be powered not only to identify the relevant
exposures but to measure change in clinical and gene
expression profiles over time. They should include
genetic, epigenetic, clinical and other physiological mea-
sures that can elucidate the mechanisms and process of
cancerogenesis. Nonlinear analytic methods should be
utilized to model the interactions.
When modeling gene-environment interactions, it is
important to remember that protective factors as well as
risk factors cause epigenetic changes. One of the most
well known protective factors with respect to cancer is
diet. Dietary nutrients such as foliate and vitamin B12
affect the availability of methyl groups for DNA methy-
lation, which is important in carcinogenesis [46-49].
DNA methylation is also inhibited by phytoestrogens
such as genistein in soy products [50] and EGCG. The
major catechin in green tea inhibits DNA methyltrans-
ferase and also reactivates expression of epigenetically
silenced genes such as RAR-beta2 [51,52]. It has been
demonstrated that treatment of cancer cells with EGCG,
can cause the demethylation of CpG islands in promoter
regions and the reactivation of methlyation-silenced
genes such as p16 [53], which is commonly hypermethy-
lated in lung cancer [54]. The methylation of histones
[55] and histone acetylation can be modified by short-
chain fatty acids, such as butyrate. These fatty acids act
as histone deacetylase inhibitors [56] and can also
increase expression of epigenetically silenced genes [57].
The fact that there are usually multiple environmental
influences at work simultaneously means that there are
effects on multiple interconnected subsystems and sig-
naling pathways and that the influences on each can
vary in multiple ways (e.g., they can be synergistic,
antagonistic, additive, etc.). This accounts for the enor-
mous complexity and temporal variation characterizing
tumor development. It also elucidates why even such a
well known risk factor as smoking only sometimes
results in cancer and why, despite this toxic exposure, it
can take many decades for lung cancer to develop. The
body utilizes multiple repair mechanisms to try to con-
tain the damage and is actually capable of stopping or
reversing the process if the smoker quits soon enough.
If there are protective factors influencing gene expres-
sion, this aids in the process.
Schipper et al., conceptualize cancer as a process of
regulatory imbalance that is potentially reversible. The
data on smoking and lung cancer supports this. The
complex process of gene expression changes in non-
mutated genes supports the theory that knock-out mod-
els are inadequate for understanding the process of
oncogenesis. The reason is that individual mutations,
DNA adducts or expression changes can be repaired,
destroyed or reversed. However, if the burden of risk
accumulates to the point of overwhelming the systems’
defenses, the result is the breakdown of repair mechan-
isms and signaling networks that initiate dysfunction.
Changes in gene expression can be responsible both for
activating oncogenes and for turning off tumor suppres-
sor genes. These expression changes occur because of
influences from the microenvironment in the cell, which
reflects and is influenced by factors originating both
inside and outside the cell and the body. It is easy to see
that this is a complex process that cannot be adequately
described or understood by focusing only on single
genes or signaling pathways.
Presentation of the Hypothesis
The hypothesis of this paper is that real progress in
treatment efficacy will not be achieved until we switch
from a reductionist paradigm of tumor etiology to a sys-
tems model. We must move to a frame of reference that
encompasses the complexity involved in tumor initiation
and progression in humans and utilize this information
to construct multidisciplinary approaches to treatment
and prevention that target the reversal of dysfunctional
process. This shift in treatment strategy requires
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complex systemic dysregulation associated with specific
cancer phenotypes, including how to identify risk factor
clusters interacting with specific genotypes, the epige-
netic and physiological precursors of tumor initiation,
and the steps required to reverse dysregulation. It
involves a shift from targeting the identification of genes
and signaling pathways involved in tumor progression to
the identification of multiple mechanisms that disable
DNA repair, apoptosis and immune function, increasing
the susceptibility of the host organism to tumorogenesis.
The mutations that are being identified in tumor pro-
gression may be the result and not the cause of tumor
initiation.
Host Susceptibility
Host susceptibility is the adaptability and responsiveness
of multiple physiological systems that facilitate the
body’s ability to maintain a dynamic equilibrium in the
face of risk factor exposure. Host susceptibility to can-
cerous changes is high when systemic adaptability is low
and the ability to respond appropriately to challenge is
reduced. Since lung cancer has well known risk factors
it is a good example for continuing the discussion of
etiologic complexity. The question is why only a minor-
ity of smokers develop lung cancer. The data seem to
point to a context of phenotypic susceptibility which
cannot be reduced to single genes or environmental fac-
tors. Given the current state of knowledge, the most
logical hypothesis is that there are both genetic and
environmental contributors to this vulnerable phenotype
that interact in complex ways that are still unclear.
Research on nicotine addiction and lung cancer has
investigated genes with both low-penetrance and high-
frequency as well as those with high-penetrance and low
frequency. A review of this field [58], reports that
although a number of loci have shown failure to repli-
cate, there are genomic regions of genetic susceptibility
to nicotine dependence on chromosomes 3-7, 9-11, 17,
20 and 22 that have been found to be suggestive or sig-
nificant in at least two independent samples. This indi-
cates that nicotinic subunit genes are plausible
contributors to phenotypic lung cancer vulnerability.
However, we also know that a distribution of pheno-
types can be produced from genetically identical cells
[11]. Therefore, in addition to genotype, factors influen-
cing gene expression would be an important area of
focus with respect to mediating mechanisms. Smoking is
the most obvious and it affects multiple systems. It has
been demonstrated to up-regulate 23 lipid metabolites,
creating a profile that is consistent with down-regulation
of alkyl-DHAP in human lung cancer tissues [59]. It also
impacts bronchial airway gene expression, heterogeneity
of which correlates with smoking-related disease risk
[60]. In non-small cell lung cancer, it has been shown
that there is a strong link between hypomethylation of
Line-1 and Alu transposons that is significantly asso-
ciated with genomic instability [61], meaning that this
epigenetic pattern creates susceptibility for mutation.
The examination of gene expression in different lung
cancer tumor types (small-cell, adenocarcinoma, squa-
mous-cell carcinoma and non-small cell lung carcino-
mas) has revealed methylation changes that reflect
multiple functional pathway s :a p o p t o s i s ,D N Ar e p a i r
(MGMT), RAS signaling, cell cycle, and invasion [54].
Furthermore, methylation rates of certain genes (e.g. p16,
APC and LCINS) differ between smokers and non-smo-
kers with lung cancer and diet influences methylation
patterns in smokers [62], indicating that gene expression
profiles are a very good measure of variation in risk
[63,64]. So it is becoming clear that smoking is asso-
ciated with multiple epigenetic changes and that these
changes interact with other epigenetic changes caused
by environmental factors (e.g., diet) that can influence
phenotypic susceptibility for lung cancer.
An additional epigenetic mechanism that is important
in lung and other cancers is loss of imprinting [11].
About 1% of human genes are imprinted, which means
that their expression is not Mendelian but determined
by the parent of origin. Autosomal imprinted genes are
structurally diploid (i.e. there is a copy from each par-
ent) but functionally haploid, meaning that only one
copy is expressed. Loss of imprinting (LOI) of IGF2 is
common in lung cancer [11,65]. One study reported
that in surgical specimens from lung cancers 6 out of 12
adenocarcinomas, 5 out of 11 squamous cell carcinomas,
2 out of 3 large cell carcinomas and 1 of 4 small cell
carcinomas exhibited loss of imprinting [66], demon-
strating that LOI is not specific to one type of lung can-
cer. Similar figures for LOI in adnenocarcinomas - 47%
were also found in another study. That study also found
LOI for mesoderm-specific tranxript (MEST) [67] and
revealed that bi-allelic expression of IGF2 was observed
even in the earliest stage tumors. Loss of imprinting of
IGF2, otherwise a normal growth promoting gene causes
its growth promoting potential to become over
expressed and oncogenic.
So how are these mechanisms related to tumor devel-
opment? It is generally accepted that solid tumors pro-
gress through multiple stages, from benign, fairly well-
differentiated tumors through stages of genetic instabil-
ity but low invasiveness, to a stage where they are meta-
static and characterized by increasing genetic changes
[33]. However, there are no known single genes or
genetic mutations that can account for this process, nor
are there any known mutations that can account for
metastasis or invasion [33]. There are however, multiple
gene expression changes that have been demonstrated
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more loss of tumor suppressor gene function may occur
through epigenetically mediated gene transcription
repression than via frank gene mutations [30,31,68].
This is exemplified by the epigenetic silencing of Hic-1
involved in modulating the activity of the p53 tumor
suppressor gene [69,70]. Importantly, it has been demon-
strated that epigenetic change precedes cancer and con-
fers risk for cancer [65].
Apoptosis
Cancer as a process is nowhere more evident than in
apoptosis or programmed cell death. Apoptosis is one of
the body’s normal mechanisms for disposing of old or
damaged cells. In healthy organisms, the rate of cell
turnover is in equilibrium. The rates of cell death and
cell proliferation are approximately balanced. In cancer,
however, the system of apoptotic signaling becomes dys-
regulated, allowing abnormal cell proliferation and facili-
tating tumor formation. Apoptosis can be a reaction to
many different types of stimuli, including but not lim-
ited to radiation, cigarette smoke, chemical pollutants or
DNA damage caused by the body’s own metabolic pro-
ducts [71]. These processes involve many systems
including micro RNAs [71-75], tumor suppressor genes
[76], BH3-only pro-apoptotic proteins as sensors of cell
damage [77], the Bcl-2 anti-apoptotic proteins
[76,78,79], the TNF receptor [80], mitochondrial pro-
cesses [81], and many, many more. It goes without say-
ing that epigenetic changes are an important part of this
process. What is more important is that these changes
are reversible [82].
Meticulous molecular research is being conducted to
understand the function of the many parts of this pro-
cess. The dynamics are so complex that a summary
would be beyond the scope of this article. However,
a p o p t o s i si sa ni m p o r t a n ta r ea for multidisciplinary
approaches because it involves key, potentially reversible
processes important in the etiology and progression of
cancer. To understand the function of individual genes,
proteins, and signaling pathways, models such as Droso-
phila are being used to control for stimuli that would
make the data on function ambiguous or difficult to
interpret. Complementing these methods with a systems
biology approach using data not only from Drosophila
but from intact animal models and humans to predict
the influence of these systems on the behavior of other
systems and verifying this experimentally, constitute
important steps in a multi-disciplinary approach. Host
susceptibility is an emergent property resulting from the
interaction of multiple complex systems. Causality is bi-
directional: not only do individual genes and signaling
pathways influence what happens to the system as a
whole, but organ systems and environmental factors
influence activity at the molecular level.
Allostatic Load
We have used the term, host susceptibility to connote
phenotypic risk for cancer. The cumulative health and
adaptability of the organism as a whole has also been
the focus of extensive research under a parallel concept,
‘allostatic load’. The term allostasis is used to describe
the dynamic ability of the body to maintain stability
through continual change and to modulate new chal-
lenge based on prior experience [83]. For example, if
there is a frequent need for response from a particular
system (e.g., the sympathetic nervous system), it may
adjust its basal activity to maintain a higher prepared-
ness or ‘vigilance’ at rest than at earlier time points
when there were fewer demands, because it is readying
itself to respond quickly to the next challenge. As long
as the demands on the body are reasonable, a state of
dynamic equilibrium and healthy functioning is main-
tained (e.g. blood pressure remains stable, plasma lipids
are within reasonable ranges, heart rate variability is
fairly high). However, coping resources can become
overwhelmed when challenges are too frequent, long
lasting or of such magnitude that they overwhelm func-
tional systems. At such times, there is enough flexibility
of function in other systems so that back-up efforts can
be directed to compensate for the overload. However,
the back-up systems pay a price by re-directing their
energy from usual tasks to help the system in need. If
the need for back-up continues, these systems may
eventually not be able to adequately perform primary
functions or to mobilize restorative mechanisms by
returning to a healthy basal level between challenges.
This can set off a chain reaction, requiring other sys-
tems to pick up the slack. If the overload continues,
feedback within and between systems, will eventually
break down. Under these conditions, even during rela-
tively quiescent periods, the body remains mobilized for
action. Allostatic load is the price that tissues and
organs pay when this over- activity causes the system to
become progressively dysregulated so that the feedback
mechanisms that normally maintain balance no longer
function optimally [84,85]. A 90 year old with multiple
co-morbidities is an example of someone with a high
allostatic load, while a healthy 20 year old athlete has a
low allostatic load. The ability of the 20 year old body
to respond with robust defenses to risk factors such as
poor diet or smoking is still strong, while that of the
90 year old is vulnerable to even mild challenge. This
m a yb ew h yt h ep r e v a l e n c eo fc h r o n i cd i s e a s e ss u c ha s
cancer and cardiovascular diseases is rare in younger
age groups: allostatic load increases with age.
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allostatic load because it shows every indication of being
a disease of cumulative burden. Smokers develop lung
cancer only after decades of exposure. In young healthy
individuals, the body mounts strong defenses and is still
able to cope with the onslaught of polycyclic aromatic
hydrocarbons present in cigarettes. Epidemiologic data
indicate that former smokers can have similar risks as
never smokers if they stop smoking early enough [86],
indicating that the lungs can repair themselves even
after years of smoking. This is very consistent with the
theory that cancer is a process of dysregulation, which is
potentially reversible, rather than a morphological entity
that must be destroyed.
Low Socioeconomic Status Contributes to Allostatic Load
The literature shows that allostatic load is elevated in
people with low socioeconomic status (SES) [87] and
that low SES is also one of the factors associated with
lung cancer [88-90] and with cancer incidence and mor-
tality in general [91-95].
Even though epidemiologic evidence shows that smok-
ing is extremely important, it also indicates that smoking
is not the only explanation for SES disparities. A prospec-
tive study of 22,387 men and women in Sweden reported
that low SES was a significant predictor of lung cancer
even after controlling for smoking, inhalation habits,a g e
and marital status [45]. Since Sweden has single payer
national health care, disparities in access to care are not a
likely explanation. Genetic factors undoubtedly play an
important role in host susceptibility as indicated earlier,
however they are less likely to account for SES disparities
in lung cancer. Although it has been shown that low SES
is associated with higher allostatic load as well as dispari-
ties in cancer morbidity and mortality, the question of
mechanism is still unclear.
Research on 1552 female twins may supply some help-
ful information. It has been shown that low SES is asso-
ciated with shorter telomere length (regions of repetitive
DNA fragments at the end of chromosomes that protect
them from replication failures) in white blood cells [96].
A pathway from DNA replication failures to mutations
might be hypothesized but still begs the question con-
cerning the association between low SES and shorter
telomere length. Is there a true association or is this an
artifact caused by a confounder?
Data suggest that the association may be real. It has
been found that low telomere length and low telomerase
activity in leukocytes are associated with exaggerated
autonomic reactivity (catecholamines and cortisol) to
acute mental stress and elevated nocturnal epinephrine
[97], showing that short telomere regions are associated
with increased secretion of stress hormones. An associa-
tion between SES and stress has also been found in
children with asthma. This is interesting because asthma
is one of the areas where unpredictable transitions from
clinically stable to unstable states occur. It has been
shown that low SES children exhibit over expression of
genes regulating stress responses and inflammatory pro-
cesses compared with asthmatic children from high SES
environments [82]. The low SES children in that study
exhibited heightened production of IL-5 and IL-13,
higher eosinophil counts and higher chronic and per-
ceived stress [98]. Thus, low SES has been associated
with psychological stress and a multilevel systemic
response ranging from gene expression changes to
immune function. Immune function is important in can-
cer and tumor infiltrating lymphocytes are considered to
represent an immune response against tumor antigens
[99]. There are also indications that lymphocyte distri-
bution in lymph nodes is a significant prognostic bio-
marker in cancer [99].
In sum, the data indicate that the association between
lung cancer and low SES is partially mediated by smok-
ing but that a significant amount of the variance
remains unexplained after adjusting for the effects of
smoking. Data also indicate that low SES is associated
with other important factors that may be contributing
to host susceptibility. Stress and the physiological
response cascade associated with it, is a strong candidate
but the association is not straightforward. The dynamics
of stress physiology are not linear. This is illustrated by
differences in immune response to acute and chronic
stress. Antigen-specific, cell-mediated immune responses
known as delayed type hypersensitivity are enhanced in
acute stress but attenuated in chronic stress [100]. This
nonlinear response is not surprising since it fits the con-
cept of allostatic load and is typical of a system that
responds powerfully to an initial stimulus but tries to
r e s e r v ee n e r g yb yr e s p o n d i n gw i t hl o w e rm a g n i t u d e
reactions to chronic, repeated challenge. What these
data indicate is that there are a whole host of risk fac-
tors that are important in the process of dysregulation.
Testing and Implications of the Hypothesis
The fact that cancerous cells can be inserted into an
animal and not develop into a tumor, reinforces the the-
ory that it is not the characteristics of the cells them-
selves, but the properties emerging from the interaction
between cells and other response systems that results in
cancer. Because many genes have multiple functions
depending on the way they are expressed, the relative
effect of individual genes is dependent on the state of
the surrounding systems and varies within defined limits
as the state changes. The same principle applies to
environmental risk factors. The effect or lack of effect
related to single factors is dependent on which other
factors are simultaneously present, the timing of
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and apoptotic defenses. Thus, treatments limited to sin-
gle components of this system (e.g. genes, hormone
receptors, signaling pathways) have a limited probability
of success.
So what is the solution? The primary focus of current
oncology research is the identification of SNPs or
genetic mutations that predict progression in already
existing tumors, or identifying genes and signaling path-
ways associated with tumor initiation in immune-com-
promised animals. Since it has become increasingly clear
that cancer is a dynamical process of dysregulation
which increases host susceptibility to tumorigenesis, a
better strategy would be to focus on systemic precursors
of cancer in non-diseased organisms. This would facili-
tate characterization of mechanisms that derail the
abundant natural defenses normally in place to prevent
tumors. This approach requires multi-disciplinary
research that encompasses a combination of basic
science, animal models that also include non-immune-
compromised animals, and human studies, including
prospective epidemiologic research in ‘at risk’ popula-
tions to characterize genetic and environmental risks,
interactions and epigenetic mechanisms. Nonlinear
mathematics and systems modeling are necessary to
assure proper analysis and interpretation of the data.
In conclusion, significantly improving treatment out-
comes will require a shift away from treatments that
‘seek and destroy’ aberrant cells, tumors, or signaling
pathways to one that tailors interventions to the com-
plex temporal sequence of gene-environment interac-
tions involved in the process of tumor initiation and
progression. Above all, it will require a paradigm shift,
moving from the goal of eliminating malignant cells, to
a model that focuses on intervening at a time point or
stage in the process where dysfunction can be reversed.
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